A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis

PHASE2TerminatedINTERVENTIONAL
Enrollment

207

Participants

Timeline

Start Date

April 26, 2018

Primary Completion Date

March 3, 2020

Study Completion Date

March 3, 2020

Conditions
Atopic Dermatitis
Interventions
DRUG

MOR 106

The active pharmaceutical drug substance of MOR106 is a human immunoglobulin gamma-1 (IgG1) monoclonal antibody that binds with a high apparent affinity to human IL-17C.

DRUG

Placebo

A sodium chloride infusion container with IV solution without addition of MOR106 drug product will be used as placebo in the proposed clinical study.

Trial Locations (53)

13086

Korsearch. Studienzentrum, Berlin

Unknown

Fachklinik Bad Bentheim, Department of Dermatology, Bad Bentheim

Charite, Universitätsmedizin Berlin, Centrum 12, Klinik für Dermatologie, Venerologie und Allergologie, Berlin

Hautarztpraxis im Jahrhunderthaus, Bochum

Hauttumorzentrum Ruhr- Universität Bochum, Bochum

RuhrDerm - Studienzentrum der Gemeinschaftspraxis für Dermatologie, Venerologie, Allergologie, Phlebologie, Bochum

Elbe Klinikum Buxtehude, Buxtehude

Universitätsklinikum Frankfurt, Klinik für Dermatologie, Frankfurt

SCIderm GmbH (a company of TFS group), Hamburg

Universitätsklinikum Heidelberg, Hautklinik, Heidelberg

Institut für Entzündungsmedizin, Lübeck

Clinical research center (CRC), Department of Dermatology, Mainz

Technical University Munich, Department of Dermatology, Munich

Klinik und Poliklinik der Dermatologie und Allergologie der Universität München, München

University Hospital of Muenster, Dpt. of Dermatology, Münster

Haut- und Lasercentrum Potsdam, Potsdam

Budai Irgalmasrendi Kórház (St. John Hospital), Budapest

Semmelweis Egyetem Bőrgyógyászati Klinika, Budapest

Bács-Kiskun Megyei Kórház Bőrgyógyászati Osztály, Kecskemét

Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház, Miskolc

Szegedi Egyetem Bőrgyógyászati és Allergológiai Klinika, Szeged

CERMED, Bialystok

Antoni Jurasz Universiti Hospital Nº1, Bydgoszcz

NZOZ Centrum Medyczne KERmed, Bydgoszcz

A-DERM-SERWIS NZOZ , Przychodnia Specjalistyczna, Częstochowa

Centrum Badań Klinicznych PI-House, Gdansk

Gyncentrum, Katowice

Centrum Medyczne ALL-MED, Krakow

Diamond Clinic, Krakow

Medical Center Dietla 19, Krakow

NZOZ Centrum Medyczne proMimed, Krakow

ETG Łódź, Lodz

Prywatny Gabinet Lekarski Urszula Chyrchel-Paszkiewicz, Lublin

Samodzielny Publiczny Szpital Kliniczny nr 1 Katedra i Klinika Dermatologii, Wenerologii i Dermatologii Dziecięcej, Lublin

Dermedic Jacek Zdybski, Ostrowiec Świętokrzyski

Ostrowieckie Centrum Medyczne, Ostrowiec Świętokrzyski

Centrum Badan Klinicznych S.C., Poznan

Centrum Medyczne Grunwald, Poznan

Clinical Research Center Sp. z o.o. Medic-R Spółka Komandytowa, Poznan

ETG Skierniewice, Skierniewice

Centrum Medyczne AMED, Warsaw

Clinical Research Group, Warsaw

ETG Warszawa, Warsaw

4HEALTH, Wroclaw

Dobrostan, Wroclaw

KLIMED Marek Klimkiewicz, Łomża

University Hospital Bratislava, Bratislava

Whipps Cross Hospital, Leytonstone

Plymouth Hospitals NHS Trust, Plymouth

Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield

The Royal London Hospital, Whitechapel

42-624

Labderm sc Beata Bergler-Czop Barbara Sido-Bergler, Ossy

93-700

KLIMED Marek Klimkiewicz, Piotrkow Trybunalski

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Galapagos NV

INDUSTRY

NCT03568071 - A Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics (PK)/Pharmacodynamics (PD) of MOR106 in Subjects With Moderate to Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter